Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

In this webinar, Dr Christos Kasparis and Professor Laura Coates discuss the management of patients with PsO and PsA with multiple manifestations and offer perspectives on the importance of timely screening and treating appropriate patients early with the right biologic. The opinion leaders also describe the Complete Cosentyx (secukinumab) Approach*, discussing clinical trial evidence from MAXIMISE for PsA, and nail and scalp data.

 

Click here for Cosentyx® (secukinumab) prescribing information

 

*The Complete Cosentyx Approach is defined as efficacy in both skin and persistent nail and scalp psoriasis, as well as psoriatic arthritis, and improvements in quality of life.

BAD, British association of dermatology; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; MTX, methotrexate.

UK | April 2021 | 117428
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]